NCT02055105 Modulation of Molecular Fingerprinting in Pediatric Sepsis
| NCT ID | NCT02055105 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Phoenix Children's Hospital |
| Condition | Systemic Inflammatory Response Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2014-03 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2014-03 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to demonstrate the sensitivity and specificity of detecting circulating micro RNA (miRNA) biomarkers in pediatric septic patients. It will also follow expression and modulation of levels in response to therapy in comparison to current biomarkers.
Eligibility Criteria
Inclusion Criteria: * Age 1 through 18 years * Patients admitted to the PICU with concerns for sepsis or those developing sepsis during their admission to the hospital. * Patients must be enrolled int he study from arrival time tot he ED up to 24 hours from the time of initiation of antibiotic therapy for treatment of sepsis or septic shock. * Signed informed consent. Exclusion Criteria: * Patients \<1 year of age and greater than 18 years of age.
Contact & Investigator
Frederick A Willyerd, MD
PRINCIPAL INVESTIGATOR
Phoenix Children's Hospital
Frequently Asked Questions
Who can join the NCT02055105 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, up to 18 Years, studying Systemic Inflammatory Response Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02055105 currently recruiting?
Yes, NCT02055105 is actively recruiting participants. Contact the research team at fwillyerd@phoenixchildrens.com for enrollment information.
Where is the NCT02055105 trial being conducted?
This trial is being conducted at Phoenix, United States, Phoenix, United States.
Who is sponsoring the NCT02055105 clinical trial?
NCT02055105 is sponsored by Phoenix Children's Hospital. The principal investigator is Frederick A Willyerd, MD at Phoenix Children's Hospital. The trial plans to enroll 50 participants.